FCGR2A and COVID-19: However, FcγR2A binding antibody with high opsonophagocytosis activity remained detectable in vaccinees over six months, pointing to the persistence of antibody effector functions following CoVLP-AS03 vaccination that may contribute to long-term protection against COVID-19.